Project Grant R21AI183178
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Ohio State University a $525,789 Project Grant effective April 1, 2026, through March 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This research initiative aims to identify bacterial isolates and microbial communities that enhance male life history traits and mating success in genetically diverse Aedes aegypti mosquitoes to support sterile insect technique (SIT) population control...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston University Medical Campus a $449,625 Project Grant on July 8, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance research on arthropod-borne viral transmission mechanisms. This two-year project, concluding July 7, 2027, will deliver a novel preclinical research model designed to better understand how mosquito feeding and arthropod-mediated...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Research Foundation For The State University Of New York $227,115 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project addressing the molecular biology of Zika virus. The award, issued February 3, 2026, with completion targeted for January 31, 2028, supports investigator-initiated research to elucidate the functional role of adenine-rich (A-rich) regions...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $439,375 Project Grant to the University of California, San Diego on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research extending through January 31, 2028. The project focuses on developing novel female-killing technologies for Aedes aegypti mosquitoes, which transmit dengue, chikungunya, and zika viruses. The research aims to...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $200,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 4, 2026, with completion targeted for January 31, 2028. The award supports investigator-initiated biomedical research focused on identifying and characterizing the ubiquitin ligase TRIM39 as a host factor...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $151,040 Project Grant award from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865) effective January 1, 2026, with a completion date of August 31, 2028. The research focuses on understanding the regulation of spermiogenesis—the process of sperm cell development and maturation—specifically investigating how the E3 ubiquitin...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $453,750 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2026. The award funds investigator-initiated biomedical research examining the role of zinc finger (ZNF) proteins in the establishment and maintenance of Human...
- Federal Project Grant Award Summary Loyola University of Chicago's Health Sciences Campus received a $781,718 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 1, 2025 through May 31, 2030. The award supports the development of a novel T cell-based vaccine designed to prevent dengue virus (DENV) and Zika virus (ZIKV) infection while avoiding antibody-dependent enhancement...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Icahn School of Medicine at Mount Sinai a $3,021,038 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 2, 2025, with a completion date of August 31, 2029. This award funds research to decipher the protective mechanisms of chemokine receptor CCR5 (C-C motif chemokine receptor 5) in maternal flavivirus infections, with specific focus on...
- This National Science Foundation (NSF) Project Grant award, funded under the Social, Behavioral, and Economic Sciences program (CFDA 47.075), aims to investigate the role of human behavior in the dynamics of mosquito-borne diseases such as dengue and Zika. The $100,000 grant, awarded to North Carolina State University (NC State), will support a multidisciplinary research project to understand how individual decision-making around mosquito prevention behaviors impacts disease transmission. The...
DETERMINANTS OF ACUTE AND PERSISTENT ZIKA VIRUS SHEDDING IN SEMEN - PROJECT SUMMARY ZIKA VIRUS (ZIKV) CAUSES CONGENITAL ZIKV SYNDROME IN INFANTS EXPOSED IN UTERO FOLLOWING MATERNAL ZIKV INFECTION VIA MOSQUITO BITE OR SEXUAL TRANSMISSION DURING PREGNANCY. IT IS ESTIMATED THAT 3-23% OF ZIKV CASES ARE DUE TO SEXUAL TRANSMISSION. MORE THAN HALF OF ZIKV-INFECTED MEN SHED ZIKV IN SEMEN, AND SOME MEN SHED ZIKV IN SEMEN FOR UP TO 6 MONTHS POST-DISEASE ONSET. IN HUMAN SEMEN, ZIKV INFECTS SEVERAL CELL TYPES INCLUDING EPITHELIAL CELLS AND IMMUNE CELLS. USING A MOUSE MODEL, INFECTION OF EPIDIDYMIS EPITHELIAL CELLS HAS BEEN SHOWN TO BE CRITICAL FOR ACUTE ZIKV SHEDDING IN SEMEN. THE ROLE OF IMMUNE CELLS IN ZIKV SHEDDING IN SEMEN IS UNKNOWN, THOUGH WE DETECTED PERSISTENT ZIKV INFECTION WITHIN THE EPIDIDYMAL LUMEN, RATHER THAN THE EPIDIDYMIS EPITHELIUM, SUGGESTING IMMUNE CELLS MAY BE CRITICAL FOR PERSISTENT ZIKV SHEDDING. THE MOST CLOSELY RELATED VIRUS TO ZIKV, SPONDWENI VIRUS (SPOV), IS POORLY SHED IN SEMEN DESPITE DISSEMINATION TO THE MALE REPRODUCTIVE TRACT. ZIKV CONTAINING THE PRM/E STRUCTURAL GENES FROM SPOV IS SHED IN SEMEN AT SIGNIFICANTLY LOWER LEVELS DURING ACUTE INFECTION. THE LONG-TERM GOAL OF THIS PROJECT IS TO UNDERSTAND THE MECHANISMS OF ZIKV SHEDDING IN SEMEN AND SEXUAL TRANSMISSION. THE OBJECTIVES OF THIS STUDY ARE TO IDENTIFY THE VIRAL FACTORS AND CELL TYPES THAT CONTRIBUTE TO ACUTE AND PERSISTENT VIRAL SHEDDING IN SEMEN. THE HYPOTHESIS IS THAT ZIKV SHEDDING IN SEMEN IS DRIVEN BY VIRAL STRUCTURAL GENES AND PERSISTENT INFECTION OF IMMUNE CELLS IN THE MALE REPRODUCTIVE TRACT. TWO SPECIFIC AIMS WILL ADDRESS THIS HYPOTHESIS: 1) DETERMINE THE ROLE OF VIRAL STRUCTURAL GENES IN ACUTE ZIKV SHEDDING IN SEMEN; AND 2) DETERMINE THE ROLE OF IMMUNE CELLS IN PERSISTENT ZIKV SHEDDING IN SEMEN. IN THE FIRST AIM, WE WILL USE OUR REVERSE GENETICS SYSTEM TO GENERATE A REVERSE GENETICS SYSTEM FOR SPOV AND A CHIMERA CONTAINING ZIKV PRM/E STRUCTURAL GENES WITHIN SPOV. VIRUSES WILL BE USED TO INFECT MALE MICE, AND VIRAL SHEDDING IN EJACULATES WILL BE MEASURED. CELL TYPES DIFFERENTIALLY INFECTED WITHIN THE EPIDIDYMIS EPITHELIUM WILL BE IDENTIFIED. IN THE SECOND AIM, MACROPHAGES WILL BE DEPLETED FROM ZIKV-INFECTED MICE DURING ACUTE AND PERSISTENT INFECTION. VIRAL SHEDDING IN SEMEN AND INFECTION OF THE EPIDIDYMIS WILL BE MEASURED. THE RESEARCH PROPOSED HERE IS INNOVATIVE BECAUSE IT ASSESSES EJACULATES, WHICH ARE BIOLOGICALLY RELEVANT SAMPLES FOR SEXUAL TRANSMISSION, AND A NOVEL ROLE FOR IMMUNE CELLS IN ZIKV SEXUAL TRANSMISSION. UPON SUCCESSFUL COMPLETION OF THE PROPOSED RESEARCH, THE ANTICIPATED CONTRIBUTION OF THIS WORK WILL BE THE IDENTIFICATION OF THE FLAVIVIRUS FACTORS THAT DICTATE VIRAL SHEDDING IN SEMEN AND THE CELL TYPES THAT CONTRIBUTE TO VIRAL SHEDDING IN SEMEN. THIS CONTRIBUTION IS EXPECTED TO BE SIGNIFICANT BECAUSE IT WILL INCREASE OUR UNDERSTANDING OF HOW VIRUSES ARE SEXUALLY TRANSMITTED.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/6/26 | ||
| Not listed | $230.4k | 4/15/25 | ||
| Not listed | $19.1k | 9/11/24 | ||
| Not listed | $19.1k | 9/11/24 | ||
| Not listed | $171.6k | 5/31/24 |